This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Cytogam, cytomegalovirus immune globulin
Description: CytoGam is an intravenous immune globulin enriched in antibodies against cytomegalovirus (CMV). CytoGam is indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas and heart. In transplants of these organs other than kidney from CMV seropositive donors into seronegative recipients, prophylactic CMV-IGIV should be considered in combination with ganciclovir.
Deal Structure: In November 2006, MedImmune announced its intent to sell CytoGam to ZLB Behring. Under the terms of a definitive agreement, ZLB Behring will make a one-time upfront payment of $50 million to MedImmune, plus equipment and inventory payments, for full worldwide rights to CytoGam. Further, an additional $70 million may be paid to MedImmune by ZLB Behring upon achievement of certain cumulative net sales milestones.
Pink Sheet In Brief: MedImmune
Pink Sheet Connaught's CMV-IG
Pink Sheet MedImmune’s CytoGam
Additional information available to subscribers only: